Marcoumar (Phenprocoumon)

Phenprocoumon blocks vitamin K epoxide reductase, an enzyme needed to recycle vitamin K. This inhibition reduces the hepatic synthesis of vitamin K‑dependent clotting factors II, VII, IX and X, prolonging clotting time and decreasing the formation of pathological blood clots.

The dose of phenprocoumon is individualized. A qualified prescriber determines the starting amount and subsequent adjustments based on regular INR monitoring, patient response, and clinical factors. No fixed regimen can be stated without a healthcare professional’s guidance.

Phenprocoumon is contraindicated during pregnancy because it can cross the placenta and cause fetal bleeding or malformations. It is also not recommended while breastfeeding, as it may be secreted in milk and affect the infant. Alternative anticoagulants should be considered for pregnant or nursing patients.

To order Marcoumar, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Both phenprocoumon and warfarin are vitamin K antagonists that require INR monitoring, but phenprocoumon has a longer half‑life, leading to more stable anticoagulation and potentially fewer dose adjustments. Warfarin may have more extensive clinical experience in some regions, while phenprocoumon is preferred in several European countries for its dosing convenience.

Marcoumar tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister or container, protect from moisture and direct light, and ensure the packaging remains tightly closed until use.

Marcoumar is taken orally, usually once daily, with or without food. The exact timing and whether it should be taken at the same time each day are determined by the prescribing clinician to maintain consistent blood levels and reliable INR monitoring.

The most serious risks include severe or life‑threatening bleeding such as intracranial hemorrhage, gastrointestinal bleeding, and spontaneous joint or muscle bleeds. Patients should be alert for unusual bruising, blood in urine or stool, severe headache, or any signs of allergic reaction, and seek immediate medical attention if they occur.

Phenprocoumon should not be used by individuals with active major bleeding, severe uncontrolled hypertension, recent major surgery, known hypersensitivity to phenprocoumon, or those who are pregnant. Patients with significant liver disease, uncontrolled thyroid disorders, or a history of hemorrhagic stroke also require careful evaluation before use.